Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 15;19(4):2203.
doi: 10.3390/ijerph19042203.

Adherence to Therapy in Patients with Multiple Sclerosis-Review

Aleksandra Kołtuniuk  1 , Justyna Chojdak-Łukasiewicz  2
Affiliations
Review

Adherence to Therapy in Patients with Multiple Sclerosis-Review

Aleksandra Kołtuniuk et al. Int J Environ Res Public Health. .

Abstract

Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating disease of the central nervous system (CNS). MS is an incurable disease. The goal of disease-modifying therapies (DMT) is to slow the progression of the disease, prevent relapses and increase the patient's overall quality of life. According to the World Health Organisation definition, adherence means the extent to which a person's medication-taking behaviour corresponds with the agreed upon treatment recommendations from a healthcare provider. Accurate adherence is necessary for efficient treatment. Non-adherence is related to unsuccessful treatments, the risk of relapses and increased healthcare costs. The aim of this study is to present the main factors relating to non-adherence in MS patients.

Keywords: adherence; disease-modifying therapy; medication; multiple sclerosis; non-adherence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Walton C., King R., Rechtman L., Kaye W., Leray E., Marrie R.A., Robertson N., La Rocca N., Uitdehaag B., Van Der Mei I., et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. J. 2020;26:1816–1821. doi: 10.1177/1352458520970841. - DOI - PMC - PubMed
    1. McGinley M.P., Goldschmidt C.H., Rae-Grant A.D. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325:765. doi: 10.1001/jama.2020.26858. - DOI - PubMed
    1. Rae-Grant A., Day G.S., Marrie R.A., Rabinstein A., Cree B.A., Gronseth G.S., Haboubi M., Halper J., Hosey J.P., Jones D.E., et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–788. doi: 10.1212/WNL.0000000000005347. - DOI - PubMed
    1. Montalban X., Gold R., Thompson A.J., Otero-Romero S., Amato M.P., Chandraratna D., Clanet M., Comi G., Derfuss T., Fazekas F., et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur. J. Neurol. 2018;25:215–237. doi: 10.1111/ene.13536. - DOI - PubMed
    1. Bevan C.J., Cree B.A.C. Disease Activity Free Status: A New End Point for a New Era in Multiple Sclerosis Clinical Research? JAMA Neurol. 2014;71:269. doi: 10.1001/jamaneurol.2013.5486. - DOI - PubMed

Publication types